<DOC>
	<DOCNO>NCT00000893</DOCNO>
	<brief_summary>Cohort I : The purpose study see safe combine 2 anti-HIV medication , efavirenz ( EFZ ) nelfinavir ( NFV ) treat HIV-positive child find appropriate dose EFZ use combination NFV . Cohort II : The purpose study see safe give EFZ syrup combine NFV measure level EFZ NFV blood . ( This purpose reflect change original since 2 different cohort patient . ) EFZ effective anti-HIV medication easily combine drug treat HIV . This early study determine safe effective dose HIV-positive child . This study also examine correct dose NFV use combination EFZ .</brief_summary>
	<brief_title>Safety , Tolerability , Anti-HIV Activity DMP 266 ( Efavirenz ) Combination With Nelfinavir HIV-Positive Children</brief_title>
	<detailed_description>The demonstrated antiviral activity , tolerability , pharmacokinetic property DMP 266 utility combination agent make DMP 266 attractive agent use HIV-infected pediatric patient . However , tolerability DMP 266 pediatric population must evaluate , appropriate dosing instruction need develop . By follow patient time , antiviral activity DMP 266-containing regimen document . Dosage guideline child develop follow analysis result . This 48-week [ AS PER AMENDMENT ( APA ) 12/21/98:104-week ] [ APA 5/8/00 : 208-week ] study . It design minimize chance ineffective therapy provide ( short dose-escalation phase ) utilize area concentration time curve ( AUC ) establish plasma level DMP 266 nelfinavir pediatric population tolerable efficacious . [ APA 5/26/98 : Patients stratify age Cohorts I II ] receive EFV concurrently NFV . [ APA 5/26/98 : The initial start dose DMP 266 patient Cohort II high initial start dose patient Cohort I . ] [ APA 12/21/98 : The initial start dose patient Stratum 1 Cohort II high initial start dose patient Cohort I Stratum 2 Cohort II . ] The initial target AUC DMP 266 190 380 micromoles/h ( uM/h ) . The initial start dose ( base 70 kg patient adjust patient 's weight ) first 6 patient adjusted basis tolerability plasma concentration DMP 266 2 week daily dos . If least 4 first 6 patient attain tolerable dose ( dose 2 6 patient experience Grade 3 bad toxicity ) target AUC , additional patient may continue accrue . However , initial 6 patient experience life-threatening toxicity , accrual suspend . [ APA 5/26/98 : An assessment tolerability plasma concentration EFV require initial group Cohort II patient . Individual dose base pharmacokinetic sampling . ] Patients receive give start dose DMP 266 continue dose individual dose adjustment need . If patient 's start dose tolerate target AUC achieve , dose increase . If start dose well tolerated target AUC achieve , adjustment start dose give future patient . If tolerate dose achieve least AUC 150 micromoles/h reach 4 6 patient , study suspend alternative dosing regimen , e.g. , twice-daily dosing , consider . A patient 's current dose DMP 266 adjust base dose tolerated whether target AUC achieve . If patient achieve AUC great 110 micromoles/h experience Grade 3 bad toxicity , patient discontinue study . [ APA 12/21/98 : The dose NFV patient Cohort I Stratum 2 Cohort II ; dose patient Stratum 1 Cohort II high . ] The minimum target AUC NFV 10 mg x h/L . Doses adjust individual child AUC fall threshold Week 2 6 . Children weight great 30 kg receive low dose child weight great 30 kg Tanner Stage IV . [ APA 5/8/00 : The first group 6 patient receive initial dose NFV . If none 6 patient fall target AUC , remainder sample accrue treat dose . If 1 6 patient fall target AUC , another group 6 patient accrue treated next high dose . If exactly 1 6 patient fall target AUC , 2 patient accrue treated dose . If 1 2 patient fall target AUC , another group 6 patient test next high dose . If neither 2 patient fall target AUC , remainder sample accrue treat dose . The dose escalate dose meet criteria achieve dose escalation prohibit due toxicity . ] The duration therapy 48 [ APA 12/21/98:104 ] [ APA 5/8/00 : 208 ] week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Inclusion Criteria Children may eligible study : Are HIVpositive . Are 3 month 16 year old ( consent parent legal guardian require ) . ( These age requirement reflect change . ) Have plasma viral load least 400 copies/ml screening . Agree practice abstinence use effective method birth control study . Are able take oral medication comply study requirement . Are take least 1 nucleoside reverse transcriptase inhibitor ( NRTI ) , zidovudine ( ZDV ) stavudine ( d4T ) . Patients begin take NRTIs begin study . Exclusion Criteria Children eligible study : Have 2 episode moderate severe diarrhea vomit last 4 day within 3 month prior study entry . Are allergic EFZ NFV . Have disease , include hepatitis , cancer , active opportunistic ( HIVassociated ) infection . Are pregnant breastfeeding . Are take experimental drug certain medication . Have ever take protease inhibitor ( PIs ) nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Area Under Curve</keyword>
	<keyword>efavirenz</keyword>
</DOC>